Prof. Naveed Sattar, MD, PhD, Metabolic Medicine, University of Glasgow, UK
In this ADA 2026 expert interview, MedJ speaks with Prof. Naveed Sattar about the translation of cardiorenal evidence into diabetes care. Drawing on his long-standing work on metabolic risk factors and cardiovascular and kidney outcomes, Prof. Sattar discusses how large cardiovascular and kidney outcome trials have influenced real-world prescribing of glucose-lowering therapies and what gaps remain between guidelines and clinical practice. He also shares his perspective on overlooked indicators or patient features that clinicians should consider when assessing residual cardiorenal risk in diabetes. In addition, Prof. Sattar reflects on his experience contributing to ESC/EASD guidelines and how guideline task forces balance the strength of evidence, breadth of applicable populations, and feasibility of implementation when developing clear clinical recommendations.